CG
LABU icon

Caprock Group’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Caprock Group’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$70K – 585
2022
Q3 		$70K Buy
+500
New +$91.7K 0.01% 556

Other funds holding LABU

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AIP
Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caprock Group's LABU Position: Q4 2022 in Review

Caprock Group sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2022, closing a stake of 500 shares — an estimated $70K sold.

Caprock Group first reported a position in LABU in Q3 2022 and held it in 1 quarter. The position peaked at $70K in Q3 2022. 49 funds tracked by Wall St. Rank hold LABU as of Q4 2022.

  • Caprock Group reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2022 after selling out during the quarter.
  • Caprock Group sold 500 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2022, an estimated $70K.
  • Caprock Group first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2022 and held it in 1 quarter.
  • Caprock Group's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $70K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2022.

Based on Caprock Group's 13F filing for Q4 2022, filed 23 Jan 2023.